4 results about "Thymosin alpha" patented technology

This invention relates to the field of biomedicine, specifically providing a mutant thymosin α1 polypeptide and its applications. The mutant differs from natural thymosin α1 by substituting at least one amino acid at positions 15, 21, and 27, with preferred mutations including D15M, E21W, and E27R. Amino acid substitutions at these sites significantly improve the structural stability and in vivo pharmacokinetic properties of thymosin α1. Experimental results show that, while maintaining the main secondary structural features and overall thermal stability without significant degradation, the mutant improves serum stability and in vivo pharmacokinetic properties, exhibiting superior in vivo half-life and antitumor activity. This invention also provides nucleic acid molecules encoding the mutant, expression vectors, host cells, and pharmaceutical compositions containing the mutant, which can be used for the treatment of tumors, viral infections, and immune-related diseases.

The invention belongs to the technical field of biological medicines, and discloses an anti-tumor polypeptide composition as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 10 to 30 parts of mucopolysaccharide combined hybrid peptide (polypeptide A) extracted from the body wall of the sea cucumber, 5 to 15 parts of angiogenesis inhibiting peptide RGD-4C, 5 to 10 parts of tumor penetrating peptide iRGD, 3 to 8 parts of thymosin alpha 1, 2 to 6 parts of ganoderma lucidum polysaccharide and 1 to 4 parts of vitamin C palmitate. Wherein the polypeptide A is prepared by a process comprising specific ultrasonication, ultrafiltration, ion exchange chromatography and reversed-phase liquid chromatography purification. The invention also provides a preparation method of the composition, which comprises the steps of weighing, sterile mixing, grinding and sub-packaging, and can be further prepared into dosage forms such as freeze-dried powder injection and the like. The composition can be used for preparing medicines for treating solid tumors such as lung cancer, breast cancer, colorectal cancer, liver cancer and the like through synergism of multiple components and multiple target points, and can be combined with chemotherapeutic medicines such as paclitaxel and the like.

This invention belongs to the field of bioengineering technology, specifically relating to a gene for efficiently expressing thymosin α1 (Tα1), recombinant lactic acid bacteria, and their applications. This invention provides a Tα1 encoding gene specifically optimized for *Lactococcus lactis* NZ9000, which significantly improves expression efficiency in the host through full-sequence codon adaptation. This gene was cloned into the vector pNZ8148-M, constructing the recombinant expression plasmid NZ9000 / pNZ8148-M. usp45 + T α1 The strain was successfully transformed into the host bacterium NZ9000, yielding recombinant lactic acid bacteria NZ9000 / pNZ8148-M. usp45 + Tα1 This recombinant strain can efficiently secrete the Tα1 fusion protein USP under Nisin induction. 45 +Tα1, the protein is digested in vitro by enterokinase to release active Tα1. The Tα1 produced by the method of this invention has high yield, high purity, high biological activity and excellent safety, providing a new technical platform for the low-cost, large-scale and safe production of Tα1.

The invention belongs to the technical field of biology, and particularly relates to thymosin alpha 1 six-string protein, an expression vector, genetically engineered bacteria, an expression method and application. The amino acid sequence of the thymosin alpha1 hexangulosomal protein provided by the invention is shown as SEQ ID No.1, and the thymosin alpha1 hexangulosomal protein has excellent immunological enhancement activity and in-vivo stability, and can be directly used for improving the autoimmunity of animals and reducing the morbidity of diseases caused by viruses or bacteria and the like, so that the use of antibiotics is reduced, and the cost is reduced. Moreover, the thymosin alpha1 hexangulosomal protein can be obtained through a genetic engineering recombination method, is low in separation and purification difficulty, simple in production process, low in production cost and easy for industrial production, and has a very good market transformation prospect. By utilizing the expression vector pET-21a-6T alpha 1 provided by the invention, a genetically engineered bacterium capable of realizing soluble expression of the six-string protein of the thymosin alpha 1 can be obtained. The high-purity thymosin alpha 1 six-string body protein can be obtained by fermenting the genetically engineered bacterium and separating and purifying the genetically engineered bacterium.